Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

NCT00684411 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

T Cell Non-Hodgkin Lymphoma

Interventions

DRUG: Imatinib mesylate

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]